# OnCo record antigen-escape (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/antigen-escape/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "antigen-escape" ;
  schema:name "Antigen escape (antigen loss, lineage switch)"@en ;
  schema:alternateName "antigen escape"@en, "antigen loss"@en, "antigen-negative relapse"@en, "CD19-negative relapse"@en, "CD19-negative"@en, "BCMA-negative"@en, "BCMA loss"@en, "target loss"@en, "target downregulation"@en, "antigen downregulation"@en, "antigen-low"@en, "lineage switch"@en, "lineage plasticity"@en, "trogocytosis"@en, "antigen heterogeneity"@en, "antigen-negative"@en ;
  schema:description "When a cancer treated with a therapy aimed at one surface marker (CD19, BCMA, HER2) survives by shedding that marker, so the drug has nothing to grab. About a third of relapses after CD19 CAR-T are antigen-negative."@en ;
  schema:url <https://onco.cc/terms/antigen-escape/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell> ;
  schema:citation <https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell> ;
  onco:related <https://onco.cc/terms/t-cell-exhaustion-term/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/flow-cytometry/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/logic-gated-therapeutics/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/> .